Trade Nektar Therapeutics - NKTR stock price

74.46
-0.03%
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreements with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, and Bristol-Myers Squibb Company. The company was founded in 1990 and is headquartered in San Francisco, California.
White Paper Declaration

NKTR price history

Date Close Change Chg% Open Min. Max.
2022-09-30 73.47 -1.15 -1.54 74.62 73.18 74.75
2022-09-30 76.1 3.86 5.34 72.24 72.13 76.26
2022-09-30 72.47 2.14 3.04 70.33 70.3 73.59
2022-09-30 71.37 2.07 2.99 69.3 69.3 72.25
2022-09-30 70.89 0.32 0.45 70.57 69.59 71.61
2022-09-30 72.44 -0.87 -1.19 73.31 70.76 73.75
2022-09-30 74.33 0.79 1.07 73.54 72.31 74.91
2022-09-30 73.12 -0.44 -0.60 73.56 73.05 74.45
2022-09-30 74.44 1.54 2.11 72.9 72.9 76.12
2022-09-30 73.28 1.03 1.43 72.25 70.46 73.95
2022-09-30 73.54 -1.05 -1.41 74.59 72.34 75.53
2022-09-30 74.12 -1.26 -1.67 75.38 72.66 75.67
2022-09-30 75.28 0.89 1.20 74.39 72.78 75.87
2022-09-30 73.53 2.51 3.53 71.02 69.92 74.57

Mobile app

Full trading account functionality: order execution and cancellation, stop-loss and take-profit setup, transaction history, deposits and withdrawals

iOS
4,7
12 127 reviews
Android
4,1
9 795 reviews
Go help.dzengi.com
Dzengi Exchange
Trade BTC & tokenized stocks